Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 20/20 | 0.70 |
| ▸ | AVPR1A | P37288 | 3/20 | 0.59 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.59 |
| ▸ | OXTR | P30559 | 2/20 | 0.59 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4087699 | 0.91 | AVPR1B (0.64) | AVPR1BAVPR1AAVPR2OXTRGPR65 | |
| SCHEMBL4087696 | 0.91 | AVPR1B (0.64) | AVPR1BAVPR1AAVPR2OXTRGPR65 | |
| SCHEMBL4077598 | 0.91 | AVPR1B (0.66) | AVPR1BAVPR1AAVPR2OXTRGPR65 | |
| SCHEMBL4082430 | 0.90 | AVPR1B (0.85) | AVPR1BAVPR1AAVPR2OXTRGPR65 | |
| SCHEMBL4417786 | 0.87 | AVPR1B (0.64) | AVPR1BAVPR1AAVPR2OXTRGPR65 | |
| SCHEMBL4085240 | 0.85 | AVPR1B (0.77) | AVPR1B | |
| SCHEMBL4082777 | 0.85 | AVPR1B (0.76) | AVPR1B | |
| SCHEMBL4086346 | 0.84 | AVPR1B (0.74) | AVPR1B | |
| SCHEMBL4082337 | 0.83 | AVPR1B (0.62) | AVPR1BAVPR1AAVPR2OXTRGPR65 | |
| SCHEMBL4087669 | 0.83 | AVPR1B (0.84) | AVPR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8431567-B2 | Substituted oxindole derivatives and their use as vasopressin and/or oxytocin receptor ligands | ABBOTT GMBH & CO. KG (DE) | 2013-04-30 | — | — | US | disclosed |
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2009-12-24 | — | — | US | disclosed |
| EP-2066657-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | Abbott GmbH & Co. KG (DE) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008025735-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | ABBOTT GMBH & CO. KG (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318406-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AND THEIR USE AS VASOPRESSIN AND/OR OXYTOCIN RECEPTOR LIGANDS | OXTR, AVPR2, AVPR1B | AVPR1B 3/4885AVPR1A 4/4885AVPR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.